Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 65 of 151

  1. Hyperpolarized Xe129

    Regeneron UK Limited

    Pulmonary Artery Hypertension

    phase 2 small molecule terminated

    1 trial

  2. Hypofractionated radiation/chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer

    phase 2 other completed

    1 trial

  3. I-124-CLR1404

    Cellectar Biosciences

    Glioblastoma

    phase 2 small molecule terminated

    1 trial

  4. I-131-CLR1404 Injection

    Cellectar Biosciences

    Glioma

    phase 2 small molecule terminated

    1 trial

  5. I3Y-MC-JPCS

    Eli Lilly Co.

    Relapsed/Refractory Solid Tumors

    phase 2 small molecule active

    1 trial

  6. I3Y-MC-JPEH

    Eli Lilly Co.

    Glioma

    phase 2 small molecule active

    1 trial

  7. I5T-MC-AACI

    Eli Lilly Co.

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  8. I7P-MC-DSAG

    Eli Lilly Co.

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  9. I8F-MC-GPIG

    Eli Lilly Co.

    Chronic Kidney Disease, CKD, Obesity, Overweight, T2D, Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  10. IAH0968

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Solid Tumor

    phase 2 mab active

    1 trial

  11. IAP0971

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial

  12. IAP0971

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Bladder Cancer

    phase 2 small molecule active

    1 trial

  13. IB 2018-04

    The George Institute

    Adult patients with locally advanced/unresectable and/or metastatic soft-tissue leiomyosarcomas.

    phase 2 small molecule active

    1 trial

  14. IB 2019-01

    The George Institute

    Adult participants with metastatic (advanced) solid tumors.

    phase 2 small molecule active

    1 trial

  15. IB 2019-03

    The George Institute

    Adult participants with advanced unresectable or metastatic soft-tissue sarcoma.

    phase 2 small molecule active

    1 trial

  16. IB 2019-04

    The George Institute

    Adult participants with metastatic or unresectable locally advanced solid tumors.

    phase 2 small molecule active

    1 trial

  17. IB 2019-07

    The George Institute

    Patients with locally advanced or metastasic Non-Small Cell Lung Carcinoma.

    phase 2 small molecule active

    1 trial

  18. IB 2020-02

    The George Institute

    Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma.

    phase 2 small molecule active

    1 trial

  19. IB 2020-05

    The George Institute

    Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcomas.

    phase 2 small molecule active

    1 trial

  20. IB 2021-01

    The George Institute

    Adult patients with treatment-naïve surgically non-metastatic and resectable primary retroperitoneal, limbs and trunk wall undifferentiated pleomorphic sarcomas.

    phase 2 small molecule active

    1 trial

  21. IB 2021-03

    The George Institute

    Adult patients with intermediate unfavorable risk prostate cancer as per NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Prostate Cancer. Version 2.2021)

    phase 2 small molecule active

    1 trial

  22. IB 2023-02

    The George Institute

    Adult patients with locally advanced/metastatic solid tumors

    phase 2 small molecule active

    1 trial

  23. IBB0979

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  24. IBB0979

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial

  25. IBD0333

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    MTD

    phase 2 mab active

    1 trial

  26. IBI3016

    Innovent Biologics (Suzhou) Co.

    Hypertension

    phase 2 small molecule active

    2 trials

  27. IBI363

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  28. IBI363

    The First People's Hospital of Lianyungang

    Advan'ce'd

    phase 2 small molecule active

    1 trial

  29. IBRUTINIB

    Fondazione Telethon ETS

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or CLL-like monoclonal B-cell lymphocytosis

    phase 2 small molecule active

    1 trial

  30. IC 2009-04

    The George Institute

    Retinoblastoma

    phase 2 small molecule active

    1 trial

  31. IC 2011-05

    The George Institute

    Retinoblastoma

    phase 2 small molecule active

    1 trial

  32. IC 2019-02

    The George Institute

    Primary Central Nervous System Lymphoma (PCNSL)

    phase 2 other active

    1 trial

  33. IC 2019-05

    The George Institute

    Ocular conservative treatment for retinoblastoma

    phase 2 small molecule active

    1 trial

  34. IC 2020-06

    The George Institute

    Metastatic uveal melanoma

    phase 2 other active

    1 trial

  35. IC 2022-07

    The George Institute

    Breast cancer

    phase 2 small molecule active

    1 trial

  36. IC 2024-01

    The George Institute

    HER3-mutant and HER2-not amplified metastatic breast cancer

    phase 2 small molecule active

    1 trial

  37. ICI21/00031

    The George Institute

    Actinic keratoses

    phase 2 small molecule active

    1 trial

  38. ICO-2020-01 REPAIR

    CERO THERAPEUTICS HOLDINGS, INC.

    RElapse in previously irradiated Prostate bed

    phase 2 other active

    1 trial

  39. ICO-2023-10

    CERO THERAPEUTICS HOLDINGS, INC.

    gastric and gastro-oesophageal junction adenocarcinomas

    phase 2 small molecule active

    1 trial

  40. ICO-2023-14

    CERO THERAPEUTICS HOLDINGS, INC.

    Patients with newly diagnosed advanced peritoneal metastasis from colon and colorectal junction cancer

    phase 2 small molecule active

    1 trial

  41. ICO-N-2013-03

    CERO THERAPEUTICS HOLDINGS, INC.

    Breast cancer

    phase 2 small molecule active

    1 trial

  42. ICONICplus

    The George Institute

    Alcohol dependence

    phase 2 small molecule active

    1 trial

  43. ICP-022

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  44. ICP-022

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  45. ICP-CL-00609

    Lacuna Pharma Pty Ltd

    Prurigo Nodularis

    phase 2 small molecule active

    1 trial

  46. ICY0123

    Dompe' Farmaceutici S.p.A.

    Atopic keratoconjunctivitis (AKC)

    phase 2 small molecule active

    1 trial

  47. ID-078A205

    Lacuna Pharma Pty Ltd

    Insomnia Disorder

    phase 2 small molecule active

    1 trial

  48. IDE196-009

    IDEAYA Biosciences

    Uveal Melanoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.